-
-
Overview
-
Specificity: Detects human CD14. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atibuclimab.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG4 Isotype Control (IB4) [ICH2257]
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
RUO atibuclimab is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis. It acts as a pattern recognition receptor for bacterial cell wall components in gram-positive and negative bacteria. CD14 antibody action stimulates a pro-inflammatory cytokine cascade often associated with inflammation in sepsis. Atibuclimab neutralization of this antibody results in the inhibition of TNF-a, IL-6 and IL-10, dampening systemic inflammatory responses. Atibuclimab also delays the release of sTNFR(1) and IL-1ra.
-
- Properties
- Applications
-
Overview